PSTX Poseida Corp Company Short-Term Debt

Poseida Therapeutics, Inc. - graphic logo of issuer PSTX

The price trend for Poseida Therapeutics (PSTX) shown in this chart reflects the dynamics of an asset valued at 0.00. Poseida Therapeutics is developing non-viral gene delivery systems via piggyBac technology to reduce production costs. Monetization is driven by DNA modification patents and deals with industry behemoths. However, high laboratory expenses are currently absorbing primary payouts, limiting the business's current profitability.

PSTX poseida.com Short-Term Debt (07/04/2022 - 01/18/2025)

Analytical breakdowns and data insights for company Poseida Corp (PSTX)

- current quotes and average value forecast:
Price Chart Poseida Therapeutics, Inc.|PSTX - Average Forecast Price
- market capitalization data:
Market Value Poseida Therapeutics, Inc.|PSTX - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Poseida Therapeutics|PSTX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio poseida.com|PSTX - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio Poseida Therapeutics|PSTX - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Poseida Therapeutics|PSTX - Aggregate Debt Obligations|Debts to Book Capitalization Poseida Therapeutics, Inc.|PSTX - Company Long-Term Liabilities|Company Short-Term Debts Poseida Therapeutics|Quick Liquidity poseida.com
- earnings and multiples data:
PSTX - Company Net Income
General company analysis:Poseida Therapeutics, Inc. (PSTX)
Flagship merchandise of poseida.com

A conservative investor assesses the fundamental stability of Poseida Therapeutics (PSTX) by monitoring liquidity and the ability to service current liabilities. This metric aggregates all debts with a maturity of up to one year, and an analysis of short-term balance sheet liabilities allows for an assessment of the company's financial cushion amid geopolitical risks affecting raw material costs and the conduct of international clinical trials.

Competitor analysis

LEGN - Company Short-Term Debt|Short-Term Debt Sana Biotechnology Inc|Autolus Pharma (AUTL) - Company Short-Term Debt|ALLO (Allogene Corp) - Company Short-Term Debt|Company Short-Term Debt Cartesian Therapeutics|Short-Term Debt Cellectis Biotherapeutics CLLS|Company Short-Term Debts CRBU|Instil Bio Inc. (TIL) - Short-Term Indebtedness|Genenta Science - Company Current Liabilities|Century Tx (IPSC) - Short-Term Debt|JSPR: Company Current Liabilities|Company Short-Term Loans and Borrowings SNTI (Senti Biosciences, Inc.)|ADAP: Company Short-Term Debts|Company Current Liabilities CERo Therapeutics Holdings|TCRT (Alaunos Therapeutics Inc.) - Company Short-Term Debts|Short-Term Debt Achilles Tx ACHL|Company Short-Term Debt CARGO Therapeutics (CRGX)|Company Short-Term Debt TSVT (2seventybio.com)|Company Short-Term Debt Gracell Biotechnologies Inc. GRCL